Terminology · March 2026 release · B3 and C3 · 2026-03-01

WHODrug Global

Maintained by Uppsala Monitoring Centre

What it helps you do

Use WHODrug when you need medicinal-product names, ingredients, countries, marketing authorization holders, strengths, ATC classifications, and drug groupings for medication coding.

  • Clinical
  • Regulatory
PlanAcquireHarmonizeExchangeLearn + reuse

01

Where it fits—and where it doesn’t

Use these four checks before committing implementation time.

Use it when
Concomitant medication, prior therapy, exposure, and pharmacovigilance drug coding across global clinical programs.
Do not use it as
Do not treat WHODrug as a complete solution on its own. Dictionary data require a subscription, ambiguous product names still need expert review, B3/C3 choices affect granularity, and up-versioning can change records and classifications.
Best for
Teams working with Clinical and Regulatory data across Acquire → Harmonize → Exchange → Learn + reuse.
Maturity
EstablishedEstablished enough for serious use; still pin the exact release and any implementation profile.

02

See it in the workflow

A standard creates value by changing a handoff, not by existing in a catalog.

  1. InputWhat starts

    Clinical and Regulatory data, metadata, and the local decisions around them

  2. WHODrugWhat changes

    WHODrug applies a shared terminology across Acquire → Harmonize → Exchange → Learn + reuse

  3. OutputWhat becomes possible

    A more consistent, reviewable handoff for the next system or team

Readiness gateBefore scaling: Dictionary data require a subscription, ambiguous product names still need expert review, B3/C3 choices affect granularity, and up-versioning can change records and classifications.

03

A concrete example

A study codes verbatim medication names to a frozen WHODrug release and format while retaining the original text, selected record, ATC choice, and reviewer decision.

Why it matters: Standardized product identity improves exposure features, but automated coding confidence, country context, dose, route, timing, and indication must remain explicit.

04

What it fits with

The March 2026 release adds IDMP-linked data and mappings; ATC supports aggregation; B3 and C3 expose different product granularity.

05

Implementation starter

Start with one bounded handoff. Pin, test, and review it before scaling.

  1. Name an accountable owner and the decision WHODrug must support.

  2. Pin the exact version and companion artifacts: March 2026 release · B3 and C3 · 2026-03-01.

  3. Map one representative input to the required terminology artifacts.

  4. Test the result against the canonical source and record every exception.

  5. Preserve the source data, mappings, and review evidence before scaling.

06

Limitation to test first—and the tests that catch it

Risk

Dictionary data require a subscription, ambiguous product names still need expert review, B3/C3 choices affect granularity, and up-versioning can change records and classifications.

Test

Run one representative end-to-end pilot and record exactly where WHODrug loses context, needs an extension, or depends on another standard.

Risk

A structured or machine-readable result can still be unfit for analysis or AI.

Test

Test the output for missing context, provenance, terminology alignment, time leakage, and the intended downstream decision. Standardized product identity improves exposure features, but automated coding confidence, country context, dose, route, timing, and indication must remain explicit.

07

Why we believe this

Checked against the canonical source plus implementation or adoption evidence reported by the steward or its community.

Evidence notation: E1 + E3. The code is shorthand; the plain-language statement above is the claim.

Formal status
Current March 2026 WHODrug Global release in B3 and C3
Confidence
High
Review state
Source-checked · watch
Reviewed by
Medicinal-product coding reviewer
Last verified
13 July 2026
Review again when
Each March or September release or format, IDMP-link, ATC, structural, or license change
How the evidence method works

08

Source shelf

Official diagrams, examples, specifications, and explainers. Nothing external loads until you choose to open it.

  • Primary sourceMarch 2026 release · B3 and C3 · 2026-03-01

    UMC What’s New in WHODrug · March 2026

    The canonical publisher or steward source used to verify this terminology profile.

    Publisher
    Uppsala Monitoring Centre
    Rights
    Rights remain with the publisher; this knowledge base links to the source rather than copying it.
    Access
    Opens the publisher's source in a new tab; no external media loads on this page.
    Verified
    2026-07-13
    Open at source

Next action

Put this profile in context

Compare its role with adjacent standards or place it inside an end-to-end data pathway before choosing an implementation.